We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

Canada markets closed
All Screeners/

TOP_MUTUAL_FUNDS_CA

Matching Mutual Funds1-25 of 24262 results
Share
Results were generated a few mins ago. Pricing data is updated frequently. Currency in USD
Symbol
NameChange% ChangePrice (Intraday)50 Day Average200 Day Average3-Mo ReturnYTD Return52 Week Range
0P000080A1.TO
SaskWorks Venture Fund Resources Class R-Series A+0.90+6.21%14.4411.6411.5920.72%58.36%
0P0001LJ2D.TO
Concentric Black Creek International Equity GIF 75/100+0.56+5.88%9.449.9710.10-2.25%N/A
0P0001LJ2F.TO
Concentric Black Creek International Equity GIF 75/75+0.53+5.56%9.479.9910.11-2.42%N/A
0P0001LJ2E.TO
Concentric Black Creek International Equity GIF 75/100 F-CL+0.49+5.14%9.5110.0210.13-2.66%N/A
0P0001LJ2X.TO
Concentric CI International Value GIF 75/100+0.47+4.92%9.539.889.97-1.90%N/A
0P0001LJ2G.TO
Concentric Black Creek International Equity GIF 75/75 F-CL+0.46+4.79%9.5410.0510.15-2.86%N/A
0P0001LJ2Z.TO
Concentric CI International Value GIF 75/75+0.44+4.62%9.569.909.98-2.08%N/A
0P0001LJ2Y.TO
Concentric CI International Value GIF 75/100 F-CL+0.40+4.20%9.609.9310.00-2.32%N/A
0P0001LJ30.TO
Concentric CI International Value GIF 75/75 F-CL+0.37+3.87%9.639.9610.02-2.52%N/A
0P00018ICG.TO
Phillips, Hager & North Long Inflation-Linked Bond Fund O+0.52+3.76%13.8213.3013.144.69%-2.44%
0P000073MW.TO
Chou Europe+0.36+3.61%9.8911.3511.39-12.49%-8.94%
0P000072QF.TO
SaskWorks Venture Fund Diversified Class A – Series A+0.68+3.04%22.4021.2121.195.60%14.99%
0P0001KYGW.TO
Fidelity Global Value Long/Short Fund - O+0.26+2.60%9.839.8610.001.20%-6.72%
0P0001KYGZ.TO
Fidelity Global Value Long/Short Fund - S5+0.47+2.59%18.0918.3119.020.51%-9.01%
0P0001KYGX.TO
Fidelity Global Value Long/Short Fund - B+0.25+2.59%9.589.639.850.52%-9.00%
0P0001KYGY.TO
Fidelity Global Value Long/Short Fund - S8+0.45+2.59%17.4217.7318.610.49%-9.11%
0P0001D8T6.TO
Desjardins Emerging Markets Fund D+0.21+2.42%8.849.189.69-6.77%-9.04%
0P0001M2M4.TO
Desjardins Emerging Markets W+0.22+2.41%8.959.289.63-6.46%N/A
0P000083X0.TO
Desjardins Emerging Markets A+0.35+2.41%14.3414.9115.80-7.03%-9.93%
0P0001106H.TO
Desjardins Emerging Markets C+0.25+2.41%10.4310.8511.49-7.01%-9.83%
0P0001EFHX.TO
Desjardins SocieTerra Emerging Markets Equity Fund A+0.23+2.39%9.6310.1511.07-9.71%-20.46%
0P0001EFI0.TO
Desjardins SocieTerra Emerging Markets Equity Fund D+0.23+2.39%9.8110.3211.22-9.48%-19.70%
0P0001AH1C.TO
Invesco Canadian Real Return Bond Index Fund I+0.26+2.38%10.9510.7810.731.83%-0.29%
0P00011IK3.TO
Invesco Canadian Real Return Bond Index Fund D+0.25+2.37%10.6710.5110.411.64%-0.96%
0P0001EFHY.TO
Desjardins SocieTerra Emerging Markets Equity Fund C+0.23+2.37%9.6610.1811.09-9.66%-20.34%
Show 25 rows
  • PR Newswire

    Teligent Takes Strategic Steps to Recapitalize and Position Business for Success

    Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey-based specialty generic pharmaceutical company, today announced a series of strategic actions in partnership with its senior lenders and its Series C noteholders to recapitalize and enhance the Company's financial flexibility. Through these actions and with support from its senior lenders and Series C noteholders, the Company is strengthening its balance sheet while also working to raise additional capital and position itself for success, including enabling it to complete the work necessary to remediate and address the issues raised by the U.S. Food and Drug Administration (FDA) in the Warning Letter issued to the Company on November 26, 2019.

  • GlobeNewswire

    Teligent Regains Compliance with Nasdaq Filing Requirements and Nasdaq Minimum Market Value Rule

    BUENA, N.J., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, previously received notice from The Nasdaq Stock Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company not having timely filed its Quarterly Report on Form 10-Q for the three months ended September 30, 2020 (the “Form 10-Q”) with the Securities and Exchange Commission. Upon filing of the Form 10-Q on December 31, 2020, the Company regained compliance with Nasdaq Listing Rule 5250(c)(1) and this matter is now closed. In addition, on July 28, 2020, the Company received notice from Nasdaq stating that the Company was not in compliance with Nasdaq Listing Rule 5450(b)(2)(C) because the Company failed to maintain a minimum market value of publicly held shares of $15,000,000 for 30 consecutive trading days. On January 15, 2021, the Company received notice from Nasdaq confirming that for the last 10 consecutive trading days, the minimum market value of publicly held shares of the Company’s common stock has been equal to or in excess of the $15,000,000 minimum market value of publicly held shares requirement for continued listing, as required by Nasdaq Listing Rule 5450(b)(2)(C). Accordingly, Nasdaq has determined that the Company has regained compliance with Nasdaq Listing Rule 5450(b)(2)(C) and this matter is now closed. Tim Sawyer, President & Chief Executive Officer of Teligent, stated, “We are committed to maintaining our Nasdaq listing, and we are pleased that we have regained compliance with Nasdaq’s filing requirements and to see that the market value of publicly held shares of the Company’s common stock once again exceeds the requirements for Nasdaq listing.” The Company has not regained compliance with the minimum $1.00 bid price requirement for continued listing set forth in Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Rule”). The Company continues to have until June 2, 2021 to regain compliance with the Bid Price Rule. If the Company does not regain compliance with the Bid Price Rule on or before June 2, 2021, unless the Company files for and receives an extension to comply with the Bid Price Rule, the Company’s common stock will be delisted from the Nasdaq Global Select Market. The Company intends to actively monitor the closing bid price of its listed shares of common stock and, as appropriate, will consider available options to resolve the deficiency and regain compliance with the Bid Price Rule. Forward-Looking Statements This press release includes “forward-looking statements” that are intended to qualify for the safe harbors from liability provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts are statements that could be deemed forward-looking. These statements are based on current expectations, estimates, forecasts and projections about the Company’s business and the industry in which the Company operates and the beliefs and assumptions of the Company’s management. Forward-looking statements can be identified by the use of words such as “will,” “may,” “could,” “should,” “would,” “believe,” “depends,” “expect,” “goal,” “anticipate,” “forecast,” “project,” “future,” “intend,” “plan,” “estimate,” “target,” “indicate,” “outlook,” and similar expressions of future intent or the negative of such terms. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, these forward-looking statements are based on management’s current beliefs, expectations and assumptions and are subject to risks and uncertainties. These statements are based on the Company’s current beliefs or expectations and are inherently subject to various risks and uncertainties, including those set forth under the caption “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other periodic reports the Company files with the Securities and Exchange Commission. Additionally, many of these risks and uncertainties are currently amplified by and will continue to be amplified by, or in the future may be amplified by, the COVID-19 outbreak and the effects thereof on the Company’s future performance and results of operations. It is not possible to predict or identify all such risks. There may be additional risks that the Company considers immaterial or which are unknown. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements included in this press release speak only as of the date hereof and, subject to any continuing obligations under applicable law or any relevant stock exchange rules, we expressly disclaim any obligation to disseminate, after the date of this document, any updates or revisions to any such forward-looking statements to reflect any change in expectations or events, conditions or circumstances on which any such statements are based. Contact: Philip K. YachmetzTeligent, Inc. (856) 776-4632 www.teligent.com

  • GlobeNewswire

    Teligent, Inc. Announces Third Quarter 2020 Results

    BUENA, N.J., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the third quarter ended September 30, 2020.Financial HighlightsThird Quarter 2020 vs. Second Quarter 2020 * Revenues of $14.3 million, an increase of $0.8 million or 6%, on stronger demand for US topical products * Gross profit of $0.1 million, a decrease of $2.4 million driven by additional inventory reserves and write offs * Product development and research expenses of $2.4 million, an increase of $0.5 million due to API write offs for development programs not being pursued * Selling, general and administrative expenses of $6.5 million, an increase of $1.6 million or 31% driven by increased professional fee for debt and strategic consulting and bad debt expense * Operating loss of $8.8 million, an increase of $4.4 million driven by an increase of $3.1 million of cost of revenue and $1.5 million selling, general and administrative expenses * Net loss of $0.5 million, a decrease of $13.8 million driven by gain on debt restructuring * Adjusted EBITDA gain of $4.1 million, an increase of $6.3 million Third Quarter 2020 vs. Third Quarter 2019 * Revenues of $14.3 million, a decrease of $4.1 million or 22%, driven by lost contract volume and price erosion * Gross profit of $0.1 million, a decrease of $7.2 million, driven by inventory reserves and increased absorption allocations due to lower contract volume and price erosion in light of COVID-19 * Product development and research expenses of $2.4 million, an increase of $0.3 million or 15% driven by API write offs for development programs not being pursued * Selling, general and administrative expenses of $6.5 million, an increase of $1.5 million or 31% driven by increased professional fee for debt and strategic consulting and bad debt expense * Operating loss of $8.8 million, an increase of $9 million driven by a $4.1 drop in revenue and increase of $3 million cost of revenue and $1.5 million selling, general and administrative expenses * Net loss of $0.5 million, a decrease of $6.6 million driven by gain on debt restructuring * Adjusted EBITDA gain of $4.1 million, an increase of $2.0 million   Warning Letter UpdateAs part of the Company’s efforts to remediate the issues identified in the FDA’s warning letter and to strengthen its quality systems, the Company has undertaken a comprehensive review of all of its products that was completed December 15th, 2020. While the review did not identify material issues with many of the Company’s products, it did identify issues of non-conformance with respect to certain products that the Company is actively reviewing and remediating. The Company believes there will be supply disruptions or process changes with respect to these products including product recalls, long-term production pauses, short-term clear path to market production pauses, and continued production with minor process corrections. The Company believes disruptions with respect to certain of its products and the diversion of resources to remediate the product quality issues will have a negative impact on the Company’s business, financial position, results of operations and cash flows during the fourth quarter of 2020 and during 2021, including reducing its revenue, negatively impacting operating/(loss), and possibly resulting in impairment and other charges. Further, the Company anticipates that the FDA’s issuance of the warning letter and review of the Company’s processes will continue to delay the FDA’s pre-approval inspection for commercial production on the newly installed injectable line at the Buena, NJ facility. The continued failure to address the issues identified by the FDA in its warning letter and those subsequently identified by the Company in its comprehensive product quality review as well as the continued delay in obtaining the FDA’s pre-approval inspection for commercial production on the newly installed injectable line at the Buena, NJ facility will have a negative impact on the Company’s business, financial position, results of operations and cash flows.COVID-19 Response SummaryIn alignment with the directives in the state of New Jersey, as a Pharmaceutical manufacturing facility, we are considered "essential". We have and will continue to remain open as long as permitted and conditions remain safe for our employees in order to continue to supply our products to the patients that need them. Teligent has taken several preventative measures to help ensure business continuity, while maintaining safe and stable operations. We have directed all non-production, Quality or R&D employees, to continue working from home in accordance with state and local guidelines. We have implemented social distancing measures on-site at our manufacturing facility to protect employees and our products. Our employees are provided daily personal protective equipment upon their arrival to the site and we have implemented temperature monitoring services at our newly established single point of entrance. We have also implemented a more frequent sanitization process of the facility.In order to preserve cash and align manufacturing-related resources with downward adjustments made to our production schedule, we initiated a reduction in force at our Buena, NJ manufacturing facility effective June 19, 2020. In connection with the reduction, the Company terminated 53 employees and furloughed another 15 employees. The Company’s employee base after these actions, coupled with the Company-wide effort to reduce recruitment initiated earlier in the year, is down 31% from the start of the year.The Company provided terminated employees with a severance package and will continue to provide health insurance coverage to its furloughed employees. The associated one-time employee severance costs totaled $0.3 million, which were recorded in cost of revenues and product development and research expenses in the Company’s Condensed Consolidated Statement of Operations and is adjusted in the Non-GAAP measurement tables on the other one-time expense line in the nine months ended September 30, 2020. In addition, the Company decided to shift its research and development operation being performed in its Tallinn, Estonia office to its US manufacturing site at Buena, New Jersey and subsequently to wind-down its Estonia operation. In September of 2020, the Company entered into a letter of intent with its former Chief Executive Officer, a related party of the Company to sell certain of Estonia's assets, primarily lab machinery, equipment and office furniture for a sales price of $125 thousand in cash.Other Matter 2023 Series D Convertible NotesOn September 22, 2020, the Company completed the issuance of approximately $27.5 million aggregate principal amount of 2023 Series D Convertible Notes in exchange for approximately $59.0 million in aggregate principal amount, plus accrued but unpaid interest, of 2023 Series A Convertible Notes, giving effect to a 53.4% discount on the principal amount of the 2023 Series A Convertible Notes exchanged. The Company also issued approximately $0.4 million aggregate principal amount of the 2023 Series D Convertible Notes in exchange for approximately $0.5 million in aggregate principal amount, plus accrued but unpaid interest, of the Company’s outstanding 2023 Series B Convertible Notes, giving effect to a 31.9% discount on the principal amount of the 2023 Series B Convertible Notes exchanged.Following the issuance of the 2023 Series D Convertible Notes, all amounts owed with respect to the 2023 Series A Convertible Notes and 2023 Series B Convertible Notes had been paid and the related indentures and the Company’s obligations thereunder were satisfied and discharged.Holders of the 2023 Series D Convertible Notes are entitled to convert principal and accrued, unpaid interest on the 2023 Series D Convertible Notes into, at the Company’s election, cash, shares of the Company’s common stock, or a combination thereof, subject to certain limitations, at an initial conversion price per share of common stock equal to $1.50, subject to adjustment under certain circumstances.Outlook for Three Months Ending December 31, 2020 For the three months ending December 31, 2020, the Company is forecasting (i) revenue of $11.0 - $12.5 million, (ii) an operating loss in the range of $5.0 - $6.0 million, (iii) negative EBITDA in the range of $1.2 - $1.5 million and (iv) negative Adjusted EBITDA in the range of $4.5 - $4.8 million.The information included above in respect of the Company’s forecasts of operating results is subject to a number of uncertainties and risks based on the relevant assumptions and expectations, including those described below in “Cautionary Note Concerning Forward-Looking Statements.” Specifically, there is a high level of uncertainty associated with the COVID-19 pandemic along with our quality review of our product portfolio and the effects thereof on the Company’s future performance and results of operations. Any of these risks or uncertainties, including in respect of the COVID-19 pandemic and quality review of our products, could cause the Company’s actual results, performance or achievements to differ materially from those expressed or implied by the Company’s forecasts above.The above forecasts are based upon the Company’s current estimates and is subject to completion of its financial closing procedures. Moreover, this forecasted financial information has been prepared solely on the basis of information that is currently available to management. Finally, the above forecasts should not be construed as financial guidance and should not be relied upon as such.About Teligent, Inc.Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Learn more on our website www.teligent.com. Forward-Looking StatementsThis press release includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions, and other statements contained in this press release that are not historical facts and statements identified by words such as “plan,” “believe,” “continue,” “should” or words of similar meaning. Factors that could cause actual results to differ materially from these expectations include, but are not limited to: our inability to meet current or future regulatory requirements in connection with existing or future ANDAs; our inability to achieve profitability; our failure to obtain FDA approvals as anticipated; our inability to execute and implement our business plan and strategy; the potential lack of market acceptance of our products; our inability to protect our intellectual property rights; changes in global political, economic, business, competitive, market and regulatory factors; and our inability to successfully complete future product acquisitions. These statements are based on our current beliefs or expectations and are inherently subject to various risks and uncertainties, including those set forth under the caption “Risk Factors” in Teligent, Inc.’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other periodic reports we file with the Securities and Exchange Commission. Teligent, Inc. does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.Non-GAAP Financial MeasuresIn addition to reporting financial information required in accordance with U.S. generally accepted accounting principles (GAAP), Teligent is also presenting EBITDA, Adjusted EBITDA and Adjusted EBITDA before product development and research costs which are non-GAAP financial measures. Since EBITDA, Adjusted EBITDA and Adjusted EBITDA before product development and research costs are non-GAAP financial measures, they should not be used in isolation or as a substitute for consolidated statements of operations and cash flow data prepared in accordance with GAAP. In addition, Teligent's definition of EBITDA, Adjusted EBITDA, Adjusted EBITDA before product development and research costs, and adjusted net loss may not be comparable to similarly titled non-GAAP financial measures reported by other companies.Adjusted EBITDA, as defined by the Company, is calculated as follows:Net loss, plus:Depreciation expenseAmortization of intangiblesInterest expense and other expenses, netAmortization of debt issuance costs, debt discounts and debt extinguishmentImpairment chargesProvision for income taxesForeign currency exchange lossChanges in the fair value of derivativesNon-cash stock-based compensation expenseOther one-time expenseThe Company believes that Adjusted EBITDA is a meaningful indicator, to both management and investors, of the past and expected ongoing operating performance of the Company. EBITDA is a commonly used and widely accepted measure of financial performance. Adjusted EBITDA is deemed by the Company to be a useful performance indicator because it adds back non-cash and non-recurring operating expenses which have little to no bearing on the Company's cash flows, may subject to uncontrollable factors and not reflective of the Company's true operational performance.The Company uses EBITDA, Adjusted EBITDA, and Adjusted EBITDA before product development and research costs in managing and analyzing its business and financial condition. Even though it believes that these financial measurements are useful to investors in evaluating the Company's performance, it also believes these financial measurements are subject to certain shortcomings. EBITDA, Adjusted EBITDA and Adjusted EBITDA before product development and research costs do not take into account the impact of capital expenditures on either the liquidity or the financial performance of the Company or omitting share-based compensation expenses that may vary over time but represent a material portion of the overall compensation expense. Due to the inherent limitations of EBITDA, Adjusted EBITDA, and Adjusted EBITDA before product development and research costs, the Company's management utilizes comparable GAAP financial measures to evaluate the business in conjunction with EBITDA, Adjusted EBITDA and Adjusted EBITDA before product, development and research costs and encourages investors to do likewise.The Company also presents a non-GAAP financial measures of adjusted net income/(loss) and adjusted net income/(loss) per diluted share, to show the adjusted net income/(loss) when EBITDA adjustments are added back or subtracted out of the traditional GAAP reported net income/(loss). Adjusted diluted earnings per share, as defined by the Company, is equal to adjusted net income/(loss) divided by the actual or anticipated diluted share count for the applicable period. TELIGENT, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except shares and per share information) Three months ended September 30, Nine months ended September 30,  2020 2019 2020 2019          Revenue, net$14,339  $18,466  $35,372  $49,929           Costs and Expenses:        Cost of revenues14,225  11,186  33,919  28,346  Selling, general and administrative expenses6,543  5,007  18,249  15,707  Impairment charges—  —  8,373  —  Product development and research expenses2,370  2,064  6,050  7,721  Total costs and expenses23,138  18,257  66,591  51,774  Operating income/(loss)(8,799) 209  (31,219) (1,845)          Other Expense:        Foreign currency exchange gain/(loss)1,856  (2,167) 2,384  (2,458) Debt partial extinguishment of 2019 Notes—  —  —  (185) Interest and other expense, net(8,056) (5,160) (21,452) (15,262) Gain on debt restructuring10,882  —  10,882  —  Inducement loss(701) —  (701) —  Change in the fair value of derivatives4,326  —  (1,523) —  Loss before income tax expense/(benefit)(492) (7,118) (41,629) (19,750)          Income tax expense/(benefit)18  (5) 49  76           Net loss$(510) $(7,113) $(41,678) $(19,826)          Basic and diluted loss per share$(0.08) $(1.32) $(7.32) $(3.68)          Weighted average shares of common stock outstanding:        Basic and diluted shares6,082,517  5,385,041  5,690,164  5,383,531   (a)   (b)   (a ) In accordance with ASC 260-10-45-13, the Company includes the Warrants issued to its Term Loan lenders to purchase 134,667 shares of the Company’s common stock at an exercise price of $0.01 per share, from July 20, 2020 to September 30, 2020, in the number of outstanding shares used to calculate the basic and diluted loss per share for the three months ended September 30, 2020.(b) The Company includes the Warrants issued to its Term Loan lenders to purchase 134,667 shares of the Company's common stock at an exercise price of $0.01 per share from July 20, 2020 to September 30, 2020 and 538,995 shares of the Company’s common stock at an exercise of $0.01 per share from May 28, 2020 to September 30, 2020, in the number of outstanding shares used to calculate the basic and diluted loss per share for the nine months ended September 30, 2020. TELIGENT, INC. AND SUBSIDIARIES GROSS TO NET DEDUCTIONS (in thousands) Three months ended September 30, Nine months ended September 30,  2020 2019 2020 2019          Gross product sales$44,264  $41,814  $104,147  $108,550           Reduction to gross product sales:        Chargebacks and billbacks24,585  14,573  54,091  37,285  Wholesaler fees for service1,445  2,355  4,191  6,303  Sales discounts and other allowances4,302  6,658  11,769  16,371  Total reduction to gross product sales30,332  23,586  70,051  59,959           Product sales, net13,932  18,228  34,097  48,591           Contract manufacturing product sales306  167  813  1,097           Research and development services and other income100  71  462  241           Total product sales, net$14,339  $18,466  $35,372  $49,929  TELIGENT, INC. AND SUBSIDIARIES RECONCILIATION OF NON-GAAP MEASURES (in thousands)   Three months ended September 30, Nine months ended September 30,   2020 2019 2020 2019           Net loss $(510) $(7,113) $(41,678) $(19,826)           Depreciation 961  922  2,933  2,700  Amortization of intangibles 664  746  2,032  2,260  Impairment charges —  —  8,373  —  Interest expense (1) 5,673  3,585  15,198  10,605  Amortization of debt issuance costs, debt discounts and debt extinguishment 2,383  1,575  6,254  4,842  Provision for income taxes 18  (5) 49  76  EBITDA 9,189  (290) (6,839) 657            Foreign currency exchange (gain)/loss (1,856) 2,167  (2,384) 2,458  EBITDA after foreign currency exchange (gain)/loss 7,333  1,877  (9,223) 3,115  Non-cash stock-based compensation expense 137  212  795  896  Change in the fair value of derivatives (4,326) —  1,523  —  Other one-time expense 928  —  1,238  —  Adjusted EBITDA (2) 4,072  2,089  (5,667) 4,011            Product development and research expenses 2,177  1,837  5,444  6,832            Adjusted EBITDA before product development and research expenses $6,249  $3,926  $(223) $10,843  (1) Includes $13.0 million and $6.4 million of non-cash interest expense during the nine months ended September 30, 2020 and 2019, respectively.(2) Adjusted EBITDA excludes certain add backs available to the Company in calculating Consolidated Adjusted EBITDA under the terms of the Ares Loan Agreement used for determining covenant compliance. TELIGENT, INC. AND SUBSIDIARIES RECONCILIATION OF NON-GAAP ADJUSTED NET LOSS (in thousands, except share and per share information)  Three months ended September 30, Nine months ended September 30,  2020 2019 2020 2019          Net loss$(510) $(7,113) $(41,678) $(19,826)          Amortization of debt issuance costs, debt discounts and debt extinguishment2,383  1,575  6,254  4,842  Provision for income taxes18  (5) 49  76  Amortization of intangibles664  746  2,032  2,260  Impairment charges—  —  8,373  —  Foreign currency exchange (gain)/ loss(1,856) 2,167  (2,384) 2,458  Non-cash stock-based compensation expense137  212  795  896  Change in the fair value of derivative liabilities(4,326) —  1,523  —  Other one-time expense928    1,238  —  Adjusted net loss$(2,562) $(2,418) $(23,798) $(9,294)          Non-GAAP adjusted net loss per basic and diluted share$(0.42) $(0.45) $(4.18) $(1.73)  Contact:Philip K. Yachmetz Teligent, Inc. (856) 776-4632 www.teligent.com